Anstee QM - Search Results

1

Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.

Loomba R, Huang DQ, Sanyal AJ, Anstee QM, Trauner M, Lawitz EJ, Ding D, Ma L, Jia C, Billin A, Huss RS, Chung C, Goodman Z, Wong VW, Okanoue T, Romero-Gómez M, Abdelmalek MF, Muir A, Afdhal N, Bosch J, Harrison S, Younossi ZM, Myers RP. Loomba R, et al. Among authors: anstee qm. Gut. 2023 Mar;72(3):581-589. doi: 10.1136/gutjnl-2022-327777. Epub 2022 Sep 9. Gut. 2023. PMID: 36750244 Free PMC article.

2

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.

Anstee QM, Targher G, Day CP. Anstee QM, et al. Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):330-44. doi: 10.1038/nrgastro.2013.41. Epub 2013 Mar 19. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23507799 Review.

3

Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.

Dyson JK, McPherson S, Anstee QM. Dyson JK, et al. Among authors: anstee qm. J Clin Pathol. 2013 Dec;66(12):1033-45. doi: 10.1136/jclinpath-2013-201620. Epub 2013 Aug 12. J Clin Pathol. 2013. PMID: 23940130 Review.

4

Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

McPherson S, Henderson E, Burt AD, Day CP, Anstee QM. McPherson S, et al. Among authors: anstee qm. J Hepatol. 2014 May;60(5):1055-62. doi: 10.1016/j.jhep.2014.01.010. Epub 2014 Jan 18. J Hepatol. 2014. PMID: 24445215

5

Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease.

Aravinthan A, Mells G, Allison M, Leathart J, Kotronen A, Yki-Jarvinen H, Daly AK, Day CP, Anstee QM, Alexander G. Aravinthan A, et al. Among authors: anstee qm. Cell Cycle. 2014;13(9):1489-94. doi: 10.4161/cc.28471. Epub 2014 Mar 11. Cell Cycle. 2014. PMID: 24626178 Free PMC article.

6

Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.

Dyson JK, McPherson S, Anstee QM. Dyson JK, et al. Among authors: anstee qm. Postgrad Med J. 2014 May;90(1063):254-66. doi: 10.1136/postgradmedj-2013-201620rep. Postgrad Med J. 2014. PMID: 24737902 Review.

7

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. Liu YL, et al. Among authors: anstee qm. Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309. Nat Commun. 2014. PMID: 24978903 Free PMC article.

8

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. McPherson S, et al. Among authors: anstee qm. J Hepatol. 2015 May;62(5):1148-55. doi: 10.1016/j.jhep.2014.11.034. Epub 2014 Dec 1. J Hepatol. 2015. PMID: 25477264 Free article.

9

Nonalcoholic fatty liver disease: new treatments.

Hardy T, Anstee QM, Day CP. Hardy T, et al. Among authors: anstee qm. Curr Opin Gastroenterol. 2015 May;31(3):175-83. doi: 10.1097/MOG.0000000000000175. Curr Opin Gastroenterol. 2015. PMID: 25774446 Free PMC article. Review.

10

The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.

Anstee QM, Day CP. Anstee QM, et al. Semin Liver Dis. 2015 Aug;35(3):270-90. doi: 10.1055/s-0035-1562947. Epub 2015 Sep 17. Semin Liver Dis. 2015. PMID: 26378644 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

255 results

Search Page